AGTI

AGTI (Agiliti, Inc.) Analyst Note Date: 2026-06-13 Current Price: $10.05

1. Structural Readiness

Conservative Entry: Not yet defined (awaiting breakout confirmation) Aggressive/Pre-Breakout Entry: N/A (Structure is in place, but price has not yet fired the breakout signal) Breakout Level: Pending confirmation Current Price: $10.05 Extension: N/A (Price is currently consolidating within the forming structure, not extended above a breakout level) ATR Current: 0.7% (Sub-threshold volatility)

2. Thesis Layer

Thesis Classification: TACTICAL / Setup-Led Secular Thesis: None named at this date.

This is a tactical, setup-led name. There is no named macro or secular thesis driving the immediate conviction. The investment case must be judged strictly on the quality of the technical setup (the forming coil) and the underlying business fundamentals as recorded in the available evidence. We do not invent a thesis; we evaluate the setup quality and the business health in isolation.

3. The Business

Company Overview: Agiliti, Inc. delivers comprehensive healthcare technology management and service solutions across the United States. The company operates in the Healthcare Services industry, specifically within the Medical Equipment Management and Rental sector.

Business Model & Operations: The company provides a "1-vendor solution" for healthcare providers, including acute care hospitals, health systems, and integrated delivery networks. Its model relies on three primary pillars:

• On-Site Managed Services: Robust on-site management encompassing the organization, reprocessing, and logistical coordination of medical equipment directly at client facilities.
• Clinical Engineering Services: Expert maintenance, repair, and corrective actions for a wide array of medical devices, ranging from general biomedical apparatus to advanced diagnostic imaging and surgical equipment. These are available as supplemental support or fully outsourced contracts.
• Equipment Rental: Solutions for short-term needs, peak demand periods, or per-case basis, including general biomedical, specialty, and surgical equipment.

Key Business Segments & Evidence:

• Surgical Services: Focused primarily on urology procedures. Agiliti provides surgical lasers and certified laser technicians in a "pay per case" model. Management notes they hold the #1 competitive position by revenue in this segment, with access to a broad range of technologies, including exclusive rights through strong manufacturer relationships.
• Peak Need Rental: Identified as a significant driver of financial performance over the prior three years.
• Quality & Compliance: As an independent service provider, the company leverages its ISO 13485 certification and full medical device quality management system to offer customers confidence and a strong financial value proposition.

Financial Guidance & Expectations (Recorded as of 2023-11-11): Management reaffirmed full-year guidance for 2023, projecting:

• Revenue: $1.16 billion to $1.19 billion.
• Adjusted EBITDA: $260 million to $270 million.
• Adjusted EPS: $0.54 to $0.59 per share.

Management explicitly stated that "Starting in 2024, we'll begin to see clear benefits as a result of those investments," referring to a streamlined range of therapeutic support services under the Agiliti brand designed to simplify the decision process for customers and provide line-of-sight to gross margin improvements via supply chain simplification and manufacturing scale benefits. Additionally, the company noted it would "anniversary the HHS renewal pricing in Q1 of 2024."

4. Archetype and Conviction

Archetype: Growth Leader Fit: The name fits the "Growth Leader" archetype due to its #1 market position in a specific niche (urology surgical services), its expansion into a streamlined "best in class" service range, and management's explicit focus on margin improvements through scale and supply chain optimization. The business model is asset-light (service/rental) with high recurring potential through managed services contracts.

Valuation & Financial Context:

• Forward Consensus EPS (FY1): $0.63157 (as of 2026-06-12).
• Cap Bucket: Small.
• Volatility Context: The current ATR of 0.7% is sub-threshold (below the 2.5% canonical threshold). This indicates the stock is currently in a low-volatility consolidation phase. Historically, the "sweet spot" for ATR at breakout is 4–6%. The current low volatility suggests the stock is coiling, but the lack of volatility also means the "structural quality" at the moment of breakout is currently unproven.

Conviction Stack:

• Thesis Strength: Low (No named secular thesis; purely tactical).
• Evidence Quality: Moderate. The evidence base is anchored in 2023 guidance and 2026 profile data. There is a significant time gap between the specific earnings guidance (2023) and the current date (2026). While the profile confirms the business model remains intact, the specific financial performance for 2024-2026 is not detailed in the provided evidence block.
• Setup Readiness: Partial. The structure is in place, but the breakout has not fired.
• Rerating Potential: Dependent on the successful execution of the "streamlined best in class" service launch and the realization of the margin improvements management promised in 2023.

5. Invalidations, Strengths, and Gaps

What Would Strengthen the Case:

• Margin Expansion: Evidence of the "gross margin improvements" management promised in 2023 materializing in recent quarterly reports.
• Volume Surge: An increase in ATR from the current 0.7% toward the 4-6% sweet spot would confirm the structural quality of the move.

What Would Invalidate the Case:

• Guidance Miss: If recent financials show a failure to meet the forward consensus EPS of $0.63 or a contraction in the "Peak need rental" segment.

Gaps in Evidence Base:

• 2024-2026 Performance Data: The most recent specific earnings guidance is from November 2023. There is no evidence in the provided block regarding actual results for 2024, 2025, or the current 2026 period, other than the forward consensus estimate. We do not know if the "clear benefits" management promised for 2024 have been realized.
• Recent Catalysts: No specific recent news or catalysts are listed for the 2026 period.
• Detailed Financials: No specific revenue or EBITDA figures for the most recent fiscal year are provided, only the forward consensus.

PRIVATE ANALYST CALL

Judgment: Speculative Confidence: low Key risks: Sub-threshold ATR (0.7%) indicates weak momentum and unproven structural quality; Significant gap in evidence between 2023 guidance and 2026 reality; No named secular thesis to support conviction. Sizing hint: Position size should be minimal or zero until breakout confirmation; do not size based on the forming coil alone. Expected path: Price likely to remain in consolidation until volatility expands and a breakout level is tested; management expectations for margin improvements must be validated by actual results. Expected horizon: Indefinite until breakout confirmation or invalidation; likely 1-3 quarters for structural resolution.